Bardia Nourbakhsh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bardia Nourbakhsh has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
Emmanuelle Waubant
Department of Neurology, University of California, San Francisco, San Francisco, California, USA
10 shared publications- Kathryn C. Fitzgerald
Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA
10 shared publications - Emmanuelle Waubant
Department of Neurology University of California San Francisco San Francisco California USA
9 shared publications - Elias S. Sotirchos
From the Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
8 shared publications - Pavan Bhargava
Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA
8 shared publications - Peter Arthur Calabresi
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
8 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (12) , 1252-1265
Association of epiretinal membranes with disability in people with multiple sclerosis
Background: Epiretinal membranes (ERMs) consist of glial and fibrocellular tissue, potentially arising from pathologic microgliosis, macrogliosis, and/or retinal pigment epithelium (RPE) cell migration. The clinical relevance of ERMs in people with multiple sclerosis (PwMS) remains largely unstudied. Objectives: To investigate ERM prevalence and their associations with retinal layer thicknesses and disability measures in PwMS. Methods: PwMS exhibiting ERMs (ERM+) were matched 1:1 with PwMS without ERMs (ERM−) by optic neuritis (ON) history, multiple sclerosis (MS) subtype, age, sex, and race. Disability assessments included high-contrast/low-contrast letter acuity (HC-/LCLA), Expanded Disability Status Scale (EDSS), walking speed test (WST), manual dexterity test (MDT), and processing speed test (PST) scores. Results: Among 1264 participants screened (1120 PwMS and 144 healthy controls [HCs]), ERMs were observed in 206 PwMS (18.4%) and 17 HCs (11.8%). ERM+ PwMS exhibited higher EDSS (1.0 ± 0.3, p = 0.002), longer WST (0.8 ± 0.2 seconds, p < 0.001), longer MDT (2.2 ± 0.5 seconds, p < 0.001), lower PST (−3.0 ± 1.4, p = 0.08), lower LCLA (−4.2 ± 1.1 letters, p < 0.001), and lower ganglion cell-inner plexiform layer (−1.8 ± 0.8 µm, p = 0.03), inner nuclear layer (−0.8 ± 0.3 µm, p = 0.01), outer nuclear layer (−1.6 ± 0.6 µm, p = 0.01), and RPE (−0.5 ± 0.1 µm, p < 0.001) thicknesses. Higher ERM stage correlated with greater disability. Conclusion: ERMs may identify a distinct MS phenotype, potentially characterized by pathological microglial and/or macroglial activity. ERMs may be a marker of similar global processes throughout the central nervous system that potentially contribute to greater overall disability.
- 6 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (12) , 1252-1265
Open AccessAssociation of epiretinal membranes with disability in people with multiple sclerosis
Background: Epiretinal membranes (ERMs) consist of glial and fibrocellular tissue, potentially arising from pathologic microgliosis, macrogliosis, and/or retinal pigment epithelium (RPE) cell migration. The clinical relevance of ERMs in people with multiple sclerosis (PwMS) remains largely unstudied. Objectives: To investigate ERM prevalence and their associations with retinal layer thicknesses and disability measures in PwMS. Methods: PwMS exhibiting ERMs (ERM+) were matched 1:1 with PwMS without ERMs (ERM−) by optic neuritis (ON) history, multiple sclerosis (MS) subtype, age, sex, and race. Disability assessments included high-contrast/low-contrast letter acuity (HC-/LCLA), Expanded Disability Status Scale (EDSS), walking speed test (WST), manual dexterity test (MDT), and processing speed test (PST) scores. Results: Among 1264 participants screened (1120 PwMS and 144 healthy controls [HCs]), ERMs were observed in 206 PwMS (18.4%) and 17 HCs (11.8%). ERM+ PwMS exhibited higher EDSS (1.0 ± 0.3, p = 0.002), longer WST (0.8 ± 0.2 seconds, p < 0.001), longer MDT (2.2 ± 0.5 seconds, p < 0.001), lower PST (−3.0 ± 1.4, p = 0.08), lower LCLA (−4.2 ± 1.1 letters, p < 0.001), and lower ganglion cell-inner plexiform layer (−1.8 ± 0.8 µm, p = 0.03), inner nuclear layer (−0.8 ± 0.3 µm, p = 0.01), outer nuclear layer (−1.6 ± 0.6 µm, p = 0.01), and RPE (−0.5 ± 0.1 µm, p < 0.001) thicknesses. Higher ERM stage correlated with greater disability. Conclusion: ERMs may identify a distinct MS phenotype, potentially characterized by pathological microglial and/or macroglial activity. ERMs may be a marker of similar global processes throughout the central nervous system that potentially contribute to greater overall disability.
- Open Access
- 1 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (3)
Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis
Background: Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT), on rates of GCIPL atrophy in people with MS remains understudied. Objectives: To assess if ocrelizumab attenuates retinal atrophy rates, particularly GCIPL atrophy, and change in clinical measures in people with relapsing MS (PwRMS), and how this compares to natalizumab (another highly-effective DMT), as well as the related anti-CD20 therapy rituximab. Methods: PwRMS receiving ocrelizumab, natalizumab, or rituximab, untreated people with progressive MS (PwPMS), and healthy controls underwent Cirrus HD-OCT, 100% and 2.5%-contrast letter acuity (LA) assessments longitudinally. MS participants underwent Expanded Disability Status Scale (EDSS) assessments. Statistical analyses used linear mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between DMT initiation and OCT monitoring; accounting for within-subject, inter-eye correlations. Results: In ocrelizumab-treated PwRMS, GCIPL atrophy rate was −0.15 µm/year (SE = 0.03, p < 0.001, n = 88 [168 eyes]), similar to GCIPL atrophy in natalizumab- or rituximab-treated PwRMS, and healthy controls, although slower than in untreated PwPMS (−0.35 µm/year, SE = 0.04, p < 0.001, n = 40 [78 eyes]). EDSS and LA scores remained stable in ocrelizumab-treated PwRMS, and similar to natalizumab- or rituximab-treated PwRMS. Conclusion: GCIPL atrophy is attenuated and clinical function relatively stable in PwRMS treated with ocrelizumab.
- 1 July 2026
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 12 (3)
Open AccessEffect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis
Background: Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT), on rates of GCIPL atrophy in people with MS remains understudied. Objectives: To assess if ocrelizumab attenuates retinal atrophy rates, particularly GCIPL atrophy, and change in clinical measures in people with relapsing MS (PwRMS), and how this compares to natalizumab (another highly-effective DMT), as well as the related anti-CD20 therapy rituximab. Methods: PwRMS receiving ocrelizumab, natalizumab, or rituximab, untreated people with progressive MS (PwPMS), and healthy controls underwent Cirrus HD-OCT, 100% and 2.5%-contrast letter acuity (LA) assessments longitudinally. MS participants underwent Expanded Disability Status Scale (EDSS) assessments. Statistical analyses used linear mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between DMT initiation and OCT monitoring; accounting for within-subject, inter-eye correlations. Results: In ocrelizumab-treated PwRMS, GCIPL atrophy rate was −0.15 µm/year (SE = 0.03, p < 0.001, n = 88 [168 eyes]), similar to GCIPL atrophy in natalizumab- or rituximab-treated PwRMS, and healthy controls, although slower than in untreated PwPMS (−0.35 µm/year, SE = 0.04, p < 0.001, n = 40 [78 eyes]). EDSS and LA scores remained stable in ocrelizumab-treated PwRMS, and similar to natalizumab- or rituximab-treated PwRMS. Conclusion: GCIPL atrophy is attenuated and clinical function relatively stable in PwRMS treated with ocrelizumab.
- Open Access
- 11 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial
To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.
- 11 June 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
Open AccessHigh-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial
To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.
- Open Access
- 5 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (5) , 539-547
Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue
Background: Fatigue is common in multiple sclerosis and may be influenced by cardiovascular comorbidities. Objective: To test whether cardiovascular comorbidity burden relates to fatigue at baseline and over time, and to assess dose response. Methods: We analyzed prospectively collected data from MS PATHS across 10 centers. Fatigue was measured with Neuro-QoL Fatigue T -scores. Cardiovascular comorbidity was defined as a composite (any vs none) and as a count of hypertension, diabetes, and dyslipidemia. Cross-sectional associations and longitudinal trajectories were modeled using multivariable regression. Extended models also included depression, anxiety, and sleep disturbance. Results: Among 5507 participants, 49% had no cardiovascular comorbidity, 32% had one, 16% had two, and 3% had three. In minimally adjusted cross‑sectional models, any comorbidity was associated with higher fatigue (beta = 0.85; 95% CI, 0.18 to 1.53), with attenuation after adjustment for depression, anxiety, and sleep (beta = 0.20; 95% CI, −0.09 to 0.49). A graded dose response was evident across 0–3 conditions. In longitudinal analyses, effect sizes were larger and remained positive after adjustment (Any vs None: beta = 1.06 in minimal models; beta = 0.39 after adjustment), consistent with a greater comorbidity burden associated with higher fatigue over time. Conclusions: Cardiovascular comorbidity burden is associated with greater fatigue, with a dose response over time.
- 5 April 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (5) , 539-547
Open AccessCardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue
Background: Fatigue is common in multiple sclerosis and may be influenced by cardiovascular comorbidities. Objective: To test whether cardiovascular comorbidity burden relates to fatigue at baseline and over time, and to assess dose response. Methods: We analyzed prospectively collected data from MS PATHS across 10 centers. Fatigue was measured with Neuro-QoL Fatigue T -scores. Cardiovascular comorbidity was defined as a composite (any vs none) and as a count of hypertension, diabetes, and dyslipidemia. Cross-sectional associations and longitudinal trajectories were modeled using multivariable regression. Extended models also included depression, anxiety, and sleep disturbance. Results: Among 5507 participants, 49% had no cardiovascular comorbidity, 32% had one, 16% had two, and 3% had three. In minimally adjusted cross‑sectional models, any comorbidity was associated with higher fatigue (beta = 0.85; 95% CI, 0.18 to 1.53), with attenuation after adjustment for depression, anxiety, and sleep (beta = 0.20; 95% CI, −0.09 to 0.49). A graded dose response was evident across 0–3 conditions. In longitudinal analyses, effect sizes were larger and remained positive after adjustment (Any vs None: beta = 1.06 in minimal models; beta = 0.39 after adjustment), consistent with a greater comorbidity burden associated with higher fatigue over time. Conclusions: Cardiovascular comorbidity burden is associated with greater fatigue, with a dose response over time.
- 29 March 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (5) , 475-486
Influence of OSCAR-IB criteria on test–retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis
Background: Optical coherence tomography (OCT) enables evaluation of inter-eye differences (IEDs) in peri-papillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses to identify unilateral optic nerve involvement (UONI), included in the 2024 revised McDonald diagnostic criteria for multiple sclerosis (MS). Objectives: To evaluate pRNFL and GCIPL thickness test–retest reliability in scans fulfilling (SFO) versus not fulfilling (SNFO) OSCAR-IB criteria in people with MS using Spectralis SD-OCT. Methods: From 164 participants, two scans per eye per protocol (optic nerve head: pRNFL; macular volume: GCIPL) were obtained with Spectralis SD-OCT and classified as SFO or SNFO. Intra-visit intraclass correlation coefficients (ICCs) and coefficients of variation (COVs) quantified reproducibility. Results: pRNFL thicknesses from SNFO exhibited lower reliability ( n = 72, ICC = 0.827, COV = 3.38%), than from SFO ( n = 216, ICC = 0.991, COV = 1.14%). GCIPL thicknesses demonstrated excellent reliability from both SFO ( n = 199, ICC = 0.997, COV = 0.53%) and SNFO ( n = 97, ICC = 0.990, COV = 0.83%). Algorithm failure and low signal strength most affected pRNFL (COV = 7.72%) and GCIPL (COV = 3.34%) reproducibility, respectively. Conclusions: OSCAR-IB violations negligibly affected GCIPL reliability, although reduced pRNFL reliability, supporting quality control to avoid erroneous UONI, and suggesting that GCIPL measures may be more robust than pRNFL measures with Spectralis SD-OCT, in contrast to prior Cirrus HD-OCT studies.
- 29 March 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 32 (5) , 475-486
Influence of OSCAR-IB criteria on test–retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis
Background: Optical coherence tomography (OCT) enables evaluation of inter-eye differences (IEDs) in peri-papillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses to identify unilateral optic nerve involvement (UONI), included in the 2024 revised McDonald diagnostic criteria for multiple sclerosis (MS). Objectives: To evaluate pRNFL and GCIPL thickness test–retest reliability in scans fulfilling (SFO) versus not fulfilling (SNFO) OSCAR-IB criteria in people with MS using Spectralis SD-OCT. Methods: From 164 participants, two scans per eye per protocol (optic nerve head: pRNFL; macular volume: GCIPL) were obtained with Spectralis SD-OCT and classified as SFO or SNFO. Intra-visit intraclass correlation coefficients (ICCs) and coefficients of variation (COVs) quantified reproducibility. Results: pRNFL thicknesses from SNFO exhibited lower reliability ( n = 72, ICC = 0.827, COV = 3.38%), than from SFO ( n = 216, ICC = 0.991, COV = 1.14%). GCIPL thicknesses demonstrated excellent reliability from both SFO ( n = 199, ICC = 0.997, COV = 0.53%) and SNFO ( n = 97, ICC = 0.990, COV = 0.83%). Algorithm failure and low signal strength most affected pRNFL (COV = 7.72%) and GCIPL (COV = 3.34%) reproducibility, respectively. Conclusions: OSCAR-IB violations negligibly affected GCIPL reliability, although reduced pRNFL reliability, supporting quality control to avoid erroneous UONI, and suggesting that GCIPL measures may be more robust than pRNFL measures with Spectralis SD-OCT, in contrast to prior Cirrus HD-OCT studies.
- Open Access
- 19 January 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1720316
The effects of fampridine on MS-related fatigue: a systematic review
Background: Slow-release 4-aminopyridine (fampridine) has been shown to improve walking function in people with multiple sclerosis (MS). Its effect on other MS symptoms, such as fatigue, remains controversial. We performed this systematic review to summarize the evidence of the effect of fampridine on fatigue in patients with MS. Methods: PubMed, Scopus, EMBASE, Web of Science, google scholar, and ProQuest were searched for randomized trials or observational studies reporting fatigue scores before and after the treatment with fampridine. We summarized the findings of all relevant reports. Results: A literature search revealed 2,675 records; after removing duplicates, we had 1,504 records. Ninety-seven full texts were evaluated, and finally, 33 studies remained for systematic review. Most studies were done in USA, France, Germany, and Italy. The participants’ age and the duration of studies ranged between 39 and 54 years and 2 and 48 weeks, respectively. Out of 20 non-randomized or observational studies, 19 reported a benefit of fampridine in improving MS fatigue; however, only three out of 13 randomized, placebo-controlled studies showed that fampridine improved fatigue better than a placebo. Conclusion: Overwhelmingly positive results of fampridine on fatigue reported in non-randomized and observational studies are compatible with the placebo-responsiveness of fatigue in MS. Randomized, placebo-controlled studies have provided inconsistent results on the effects of fampridine on MS fatigue. Although it is possible that fatigue, at least in a subgroup of people with MS, might respond to fampridine, high-quality, placebo-controlled, blinded, randomized trials are needed to show the efficacy of this medication in improving MS fatigue.
- 19 January 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1720316
Open AccessThe effects of fampridine on MS-related fatigue: a systematic review
Background: Slow-release 4-aminopyridine (fampridine) has been shown to improve walking function in people with multiple sclerosis (MS). Its effect on other MS symptoms, such as fatigue, remains controversial. We performed this systematic review to summarize the evidence of the effect of fampridine on fatigue in patients with MS. Methods: PubMed, Scopus, EMBASE, Web of Science, google scholar, and ProQuest were searched for randomized trials or observational studies reporting fatigue scores before and after the treatment with fampridine. We summarized the findings of all relevant reports. Results: A literature search revealed 2,675 records; after removing duplicates, we had 1,504 records. Ninety-seven full texts were evaluated, and finally, 33 studies remained for systematic review. Most studies were done in USA, France, Germany, and Italy. The participants’ age and the duration of studies ranged between 39 and 54 years and 2 and 48 weeks, respectively. Out of 20 non-randomized or observational studies, 19 reported a benefit of fampridine in improving MS fatigue; however, only three out of 13 randomized, placebo-controlled studies showed that fampridine improved fatigue better than a placebo. Conclusion: Overwhelmingly positive results of fampridine on fatigue reported in non-randomized and observational studies are compatible with the placebo-responsiveness of fatigue in MS. Randomized, placebo-controlled studies have provided inconsistent results on the effects of fampridine on MS fatigue. Although it is possible that fatigue, at least in a subgroup of people with MS, might respond to fampridine, high-quality, placebo-controlled, blinded, randomized trials are needed to show the efficacy of this medication in improving MS fatigue.
- 8 December 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 106, 106915
Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort
- 8 December 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 106, 106915
Baseline predictors of sustained fatigue onset in multiple sclerosis: A longitudinal survival analysis of the MS PATHS cohort
- 19 September 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (11) , 1338-1347
Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls
Background: Whether continuous anti-CD20 therapy is required for durable disease control in relapsing multiple sclerosis (MS) is uncertain. Objective: To determine if two standard courses of ocrelizumab can sustain clinical and radiological remission and to compare outcomes with patients who continue standard-interval dosing (SID). Methods: We pooled two single-center, prospective, open-label trials (NCT03853746, NCT04261790). Nineteen adults with active relapsing MS received two ocrelizumab courses (300 mg × 2 followed 6 months later by 600 mg) and were followed for up to 46 months. Fifty-two SID recipients were propensity-matched (⩽1:3). The primary endpoint was time to disease reactivation, analyzed with restricted mean survival time (RMST) computed to a common truncation time (τ = 46 months). We also included a post-hoc comparative analysis with a retrospectively identified standard interval-dosing (SID) cohort. Results: Disease reactivation occurred in 6/19 (32%) discontinuation participants and 0/52 propensity-score-matched controls. RMST to reactivation was 40.5 months with finite dosing versus 46.0 months with SID (difference −5.5 months; 95% confidence interval [CI] –9.8 to −1.3; p = 0.011). Peripheral CD19+ B-cell repopulation (⩾1% or ⩾40 cells/μL) did not predict reactivation. Conclusion: Most patients remained clinically stable for more than 3 years after only two ocrelizumab courses. These hypothesis-generating findings warrant larger randomized or prospectively harmonized studies of finite-course anti-CD20 therapy as a de-escalation strategy in MS. Trial registration: ClinicalTrials.gov NCT03853746 and NCT04261790.
- 19 September 2025
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 31 (11) , 1338-1347
Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls
Background: Whether continuous anti-CD20 therapy is required for durable disease control in relapsing multiple sclerosis (MS) is uncertain. Objective: To determine if two standard courses of ocrelizumab can sustain clinical and radiological remission and to compare outcomes with patients who continue standard-interval dosing (SID). Methods: We pooled two single-center, prospective, open-label trials (NCT03853746, NCT04261790). Nineteen adults with active relapsing MS received two ocrelizumab courses (300 mg × 2 followed 6 months later by 600 mg) and were followed for up to 46 months. Fifty-two SID recipients were propensity-matched (⩽1:3). The primary endpoint was time to disease reactivation, analyzed with restricted mean survival time (RMST) computed to a common truncation time (τ = 46 months). We also included a post-hoc comparative analysis with a retrospectively identified standard interval-dosing (SID) cohort. Results: Disease reactivation occurred in 6/19 (32%) discontinuation participants and 0/52 propensity-score-matched controls. RMST to reactivation was 40.5 months with finite dosing versus 46.0 months with SID (difference −5.5 months; 95% confidence interval [CI] –9.8 to −1.3; p = 0.011). Peripheral CD19+ B-cell repopulation (⩾1% or ⩾40 cells/μL) did not predict reactivation. Conclusion: Most patients remained clinically stable for more than 3 years after only two ocrelizumab courses. These hypothesis-generating findings warrant larger randomized or prospectively harmonized studies of finite-course anti-CD20 therapy as a de-escalation strategy in MS. Trial registration: ClinicalTrials.gov NCT03853746 and NCT04261790.
- 15 August 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 477, 123657
Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis
- 15 August 2025
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 477, 123657
Association of paramagnetic rim lesions with patient-reported neuropsychiatric symptoms in multiple sclerosis
- 4 April 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (8) , 3469-3476
Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis
Background Ocrelizumab is an anti-CD20 monoclonal antibody that is highly effective in reducing MS clinical and radiological activity. The standard dosing regimen consists of infusing 600 mg of ocrelizumab every six months. However, concerns about increasing risks of infection and lowered vaccine response, particularly during the COVID-19 pandemic, prompted clinicians to extend the dosing interval between ocrelizumab infusions for some patients. Several observational studies have compared the effects of extended-interval dosing (EID) and standardinterval dosing (SID) of ocrelizumab on MS relapse rate and MRI activity. Method We performed a systematic review and meta-analysis of the current literature to summarize studies comparing ocrelizumab EID and SID on MS disease activity in patients with MS. Two independent reviewers searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar on the 1st of June 2024. Results Our systematic search revealed 348 records, and after deleting duplicates, 29 records remained. Twenty-eight full texts were evaluated; ultimately, 16 studies remained for systematic review. In this meta-analysis, extended interval dosing (EID) was defined variably across studies, with some considering even a one-month delay as EID. The pooled odds ratios (ORs) for clinical and MRI activity, comparing ocrelizumab EID to SID groups, were estimated as 1.04 (95%CI: 0.67-1.6, I2=30%, P=0.21) and 1.31(95%CI: 0.90-1.92) (I2=15%, P=0.32), respectively. Conclusion This systematic review and meta-analysis suggest that ocrelizumab EID is not associated with greater odds of clinical and radiological disease activity in patients with MS.
- 4 April 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (8) , 3469-3476
Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis
Background Ocrelizumab is an anti-CD20 monoclonal antibody that is highly effective in reducing MS clinical and radiological activity. The standard dosing regimen consists of infusing 600 mg of ocrelizumab every six months. However, concerns about increasing risks of infection and lowered vaccine response, particularly during the COVID-19 pandemic, prompted clinicians to extend the dosing interval between ocrelizumab infusions for some patients. Several observational studies have compared the effects of extended-interval dosing (EID) and standardinterval dosing (SID) of ocrelizumab on MS relapse rate and MRI activity. Method We performed a systematic review and meta-analysis of the current literature to summarize studies comparing ocrelizumab EID and SID on MS disease activity in patients with MS. Two independent reviewers searched PubMed, Scopus, EMBASE, Web of Science, and Google Scholar on the 1st of June 2024. Results Our systematic search revealed 348 records, and after deleting duplicates, 29 records remained. Twenty-eight full texts were evaluated; ultimately, 16 studies remained for systematic review. In this meta-analysis, extended interval dosing (EID) was defined variably across studies, with some considering even a one-month delay as EID. The pooled odds ratios (ORs) for clinical and MRI activity, comparing ocrelizumab EID to SID groups, were estimated as 1.04 (95%CI: 0.67-1.6, I2=30%, P=0.21) and 1.31(95%CI: 0.90-1.92) (I2=15%, P=0.32), respectively. Conclusion This systematic review and meta-analysis suggest that ocrelizumab EID is not associated with greater odds of clinical and radiological disease activity in patients with MS.